Business
Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate
CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the Company will host an online Key Opinion Leader (“KOL”) event on Wednesday, December 7, 2022 from 12 p.m. – 2 p.m. EST. To kick off the event, Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines, will provide a brief Company overview and deliver a welcome message to participants. Following this introduction, Ali Fattom, Ph.D., will give an introduction to vaccines, the importance and benefits of vaccines that elicit mucosal immunity, the current pneumococcal vaccine landscape, and the need for an efficacious, intranasal pneumococcal vaccine. Then, Jason Rosch, Ph.D., will introduce BWV-201, a live attenuated, serotype independent, intranasally delivered pneumococcal vaccine and data generated to date to support vaccine exploration and development. To round out the event. Dr. Fattom will present the current action plan for BWV-201 development, including milestones and timelines to reach a Phase I clinical trial. A live Q&A session will follow the formal presentation. To register for the event, please use the following link: https://app.webinar.net/0ZpQL14wxJG Dr. Ali Fattom received his Ph.D. in microbiology from the Life Science Institute at the Hebrew University of Jerusalem. He spent 5 years at John Robbins lab at the National Institutes of Health (“NIH”) working on polysaccharide conjugate pneumococcal vaccines, providing him with a strong background and expertise in pneumococcal disease. He previously served as Senior Vice President for Vaccine Research and Development at Nabi Biopharmaceutical and as Chief Scientific Officer at BlueWillow Biologics, Inc. where he led their efforts to develop viral vaccines for various infectious diseases, including HSV, RSV, and influenza. Currently, Dr. Fattom is an Adjunct Professor at the University of Michigan and serves as an independent consultant for Blue Water Vaccines, providing expertise to advance BWV’s vaccine pipeline and progress towards clinical development of vaccine candidates. Dr. Fattom is an author of over 70 peer-reviewed publications and holds over 20 patents in the field of vaccinology. Dr. Ja...